Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Seattle Genetics gets approval of TUKYSA in Switzerland for metastatic HER2-positive breast cancer

pharmaceutical-business-reviewMay 15, 2020

Tag: Seattle Genetics , Tukysa , HER2-positive breast cancer , TRASTUZUMAB , Capecitabine

PharmaSources Customer Service